<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328961</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00009750</org_study_id>
    <secondary_id>INV-016204</secondary_id>
    <nct_id>NCT04328961</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)</brief_title>
  <official_title>Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the&#xD;
      virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age&#xD;
      (inclusive) who are close contacts of persons with laboratory confirmed SARS-CoV-2 or&#xD;
      clinically suspected COVID-19. Eligible participants will be enrolled and randomized to&#xD;
      receive the intervention or placebo at the level of the household (all eligible participants&#xD;
      in one household will receive the same intervention).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, multi-center, placebo-equivalent (ascorbic acid) controlled, blinded&#xD;
      study of Hydroxychloroquine (HCQ) post-exposure prophylaxis (PEP) for the prevention of&#xD;
      SARS-CoV-2 infection in adults exposed to the virus.The overarching goal of this study is to&#xD;
      assess the effectiveness of HCQ PEP on the incidence of SARS-CoV-2 detection by polymerase&#xD;
      chain reaction (PCR) to inform public health control strategies.This study will enroll up to&#xD;
      2000 asymptomatic men and women 18 to 80 years of age (inclusive) at baseline who are close&#xD;
      contacts of persons with PCR-confirmed SARS-CoV-2 or clinically suspected COVID-19 and a&#xD;
      pending SARS-CoV-2 PCR test. Eligible participants will be enrolled and randomized 1:1 to HCQ&#xD;
      or ascorbic acid at the level of the household (all eligible participants in one household&#xD;
      will receive the same intervention). Participants will be counseled about the preliminary in&#xD;
      vitro data on HCQ activity against SARS CoV-2 and equipoise regarding efficacy in humans.The&#xD;
      duration of study participation will be approximately 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Actual">October 8, 2020</completion_date>
  <primary_completion_date type="Actual">September 24, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection</measure>
    <time_frame>Day 1 through Day 14 after enrolment</time_frame>
    <description>Polymerase chain reaction (PCR) confirmed severe acute respiratory syndrome coronavirus 2 of the genus Betacoronavirus (SARS-CoV-2) infection from self-collected samples collected daily for 14 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection</measure>
    <time_frame>Day 28 after enrolment</time_frame>
    <description>Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection from self-collected samples collected at study exit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Participant-reported Adverse Events</measure>
    <time_frame>28 days from start of Hydroxychloroquine therapy</time_frame>
    <description>Safety and tolerability of Hydroxychloroquine as SARS-CoV-2 PEP in adults</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had COVID-19 Disease</measure>
    <time_frame>28 days from enrolment</time_frame>
    <description>Participants who had a PCR-confirmed SARS-CoV-2 infection and met the Center for Disease Control (CDC) defined criteria for symptomatic COVID-19 disease.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">943</enrollment>
  <condition>COVID-19</condition>
  <condition>Corona Virus Infection</condition>
  <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Ascorbic Acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ascorbic acid 500 mg orally daily for 3 days, then 250 mg orally daily for 11 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine Sulfate</intervention_name>
    <description>Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <other_name>HCQ arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.</description>
    <arm_group_label>Ascorbic Acid</arm_group_label>
    <other_name>Placebo arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women 18 to 80 years of age inclusive, at the time of signing the informed&#xD;
             consent&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Had a close contact of a person (index) with known PCR-confirmed SARS-CoV-2 infection&#xD;
             or who is currently being assessed for COVID-19. Close contact defined as:&#xD;
&#xD;
               1. Household contact (i.e., residing with the index case in the 14 days prior to&#xD;
                  index diagnosis)&#xD;
&#xD;
               2. Medical staff, first responders, or other care persons who cared for the index&#xD;
                  case without personal protection (mask and gloves)&#xD;
&#xD;
          -  Less than 4 days since last exposure (close contact with a person with SARS-CoV-2&#xD;
             infection) to the index case&#xD;
&#xD;
          -  Body weight &lt; 100 kg (self-reported)&#xD;
&#xD;
          -  Access to device and internet for Telehealth visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to HCQ or other 4-aminoquinoline compounds&#xD;
&#xD;
          -  Currently hospitalized&#xD;
&#xD;
          -  Symptomatic with subjective fever, cough, or sore throat&#xD;
&#xD;
          -  Current medications exclude concomitant use of HCQ&#xD;
&#xD;
          -  Concomitant use of other anti-malarial treatment or chemoprophylaxis&#xD;
&#xD;
          -  History of retinopathy of any etiology&#xD;
&#xD;
          -  Psoriasis&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes&#xD;
             &lt; 1500) or thrombocytopenia (&lt; 100 K)&#xD;
&#xD;
          -  Concomitant use of digoxin, cyclosporin, cimetidine, or tamoxifen&#xD;
&#xD;
          -  Known liver disease&#xD;
&#xD;
          -  Known long QT syndrome&#xD;
&#xD;
          -  Use of any investigational or non-registered drug or vaccine within 30 days preceding&#xD;
             the first dose of the study drugs, or planned use during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruanne V. Barnabas, MBChB, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington, Coordinating Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UW Virology Research Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <results_first_submitted>October 8, 2021</results_first_submitted>
  <results_first_submitted_qc>December 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2021</results_first_posted>
  <last_update_submitted>December 14, 2021</last_update_submitted>
  <last_update_submitted_qc>December 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Ruanne Barnabas</investigator_full_name>
    <investigator_title>Associate Professor, School of Medicine: Global Health</investigator_title>
  </responsible_party>
  <keyword>novel coronavirus</keyword>
  <keyword>post-exposure prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data from the study will be made available in accordance with the funder's open access policy.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Within 3 months of publication of primary results.</ipd_time_frame>
    <ipd_access_criteria>De-identified data from the study will be made available in accordance with the funder's open access policy.</ipd_access_criteria>
    <ipd_url>https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT04328961/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT04328961/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>949 participants were assessed for eligibility, 114 were excluded and 829 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ascorbic Acid</title>
          <description>Ascorbic acid 500 mg orally daily for 3 days, then 250 mg orally daily for 11 days&#xD;
Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.</description>
        </group>
        <group group_id="P2">
          <title>Hydroxychloroquine</title>
          <description>Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days&#xD;
Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="422"/>
                <participants group_id="P2" count="407"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="336"/>
                <participants group_id="P2" count="353"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The above participants contributed to the Modified Intention-to-Treat Cohort.</population>
      <group_list>
        <group group_id="B1">
          <title>Ascorbic Acid</title>
          <description>Ascorbic acid 500 mg orally daily for 3 days, then 250 mg orally daily for 11 days&#xD;
Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.</description>
        </group>
        <group group_id="B2">
          <title>Hydroxychloroquine</title>
          <description>Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days&#xD;
Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="336"/>
            <count group_id="B2" value="353"/>
            <count group_id="B3" value="689"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="307"/>
                    <measurement group_id="B2" value="322"/>
                    <measurement group_id="B3" value="629"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="26" upper_limit="50"/>
                    <measurement group_id="B2" value="40" lower_limit="27" upper_limit="51"/>
                    <measurement group_id="B3" value="39" lower_limit="27" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="412"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="534"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="369"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="336"/>
                    <measurement group_id="B2" value="353"/>
                    <measurement group_id="B3" value="689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection</title>
        <description>Polymerase chain reaction (PCR) confirmed severe acute respiratory syndrome coronavirus 2 of the genus Betacoronavirus (SARS-CoV-2) infection from self-collected samples collected daily for 14 days</description>
        <time_frame>Day 1 through Day 14 after enrolment</time_frame>
        <population>The above participants qualified for the Modified Intention-to-Treat Cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Ascorbic Acid</title>
            <description>Ascorbic acid 500 mg orally daily for 3 days, then 250 mg orally daily for 11 days&#xD;
Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.</description>
          </group>
          <group group_id="O2">
            <title>Hydroxychloroquine</title>
            <description>Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days&#xD;
Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection</title>
          <description>Polymerase chain reaction (PCR) confirmed severe acute respiratory syndrome coronavirus 2 of the genus Betacoronavirus (SARS-CoV-2) infection from self-collected samples collected daily for 14 days</description>
          <population>The above participants qualified for the Modified Intention-to-Treat Cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection</title>
        <description>Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection from self-collected samples collected at study exit</description>
        <time_frame>Day 28 after enrolment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ascorbic Acid</title>
            <description>Ascorbic acid 500 mg orally daily for 3 days, then 250 mg orally daily for 11 days&#xD;
Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.</description>
          </group>
          <group group_id="O2">
            <title>Hydroxychloroquine</title>
            <description>Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days&#xD;
Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection</title>
          <description>Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection from self-collected samples collected at study exit</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Participant-reported Adverse Events</title>
        <description>Safety and tolerability of Hydroxychloroquine as SARS-CoV-2 PEP in adults</description>
        <time_frame>28 days from start of Hydroxychloroquine therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ascorbic Acid</title>
            <description>Ascorbic acid 500 mg orally daily for 3 days, then 250 mg orally daily for 11 days&#xD;
Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.</description>
          </group>
          <group group_id="O2">
            <title>Hydroxychloroquine</title>
            <description>Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days&#xD;
Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Participant-reported Adverse Events</title>
          <description>Safety and tolerability of Hydroxychloroquine as SARS-CoV-2 PEP in adults</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had COVID-19 Disease</title>
        <description>Participants who had a PCR-confirmed SARS-CoV-2 infection and met the Center for Disease Control (CDC) defined criteria for symptomatic COVID-19 disease.</description>
        <time_frame>28 days from enrolment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ascorbic Acid</title>
            <description>Ascorbic acid 500 mg orally daily for 3 days, then 250 mg orally daily for 11 days&#xD;
Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.</description>
          </group>
          <group group_id="O2">
            <title>Hydroxychloroquine</title>
            <description>Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days&#xD;
Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had COVID-19 Disease</title>
          <description>Participants who had a PCR-confirmed SARS-CoV-2 infection and met the Center for Disease Control (CDC) defined criteria for symptomatic COVID-19 disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected during the period of follow up, which was 28 days.</time_frame>
      <desc>Adverse event collection was obtained through daily surveys completed by participants. If participants were experiencing symptoms they were contacted by study staff for more information.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ascorbic Acid</title>
          <description>Ascorbic acid 500 mg orally daily for 3 days, then 250 mg orally daily for 11 days&#xD;
Ascorbic Acid: Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.</description>
        </group>
        <group group_id="E2">
          <title>Hydroxychloroquine</title>
          <description>Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days&#xD;
Hydroxychloroquine Sulfate: Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalizations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual Changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea, abdominal discomfort, or vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="422"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Nausea or upset stomach</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="422"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic reaction: irritability, dizziness, or vertifgo</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="422"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="422"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Hot flashes, night sweats, or palpitations</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Taste change or dry mouth</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin reaction/rash</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="422"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ruanne Barnabas</name_or_title>
      <organization>University of Washington</organization>
      <phone>206 520 3800</phone>
      <email>rbarnaba@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

